In this Issue

• Psychedelics Namechecked in Trump Cabinet Meeting
• Interview: Noma Therapy Raises $4.25M, Aims to Disrupt At-Home Ketamine With Insurance-Friendly Approach
• Interview: Christian Angermayer: Keep Politics Out of Psychedelics—And Bitcoin on the Balance Sheet
• and more…

***

On Wednesday, President Trump livestreamed a meeting in which members of his cabinet—seated around a table with various colourways of GULF OF AMERICA caps in front of them—provided updates from their first 100 days in office.

When the circle reached VA Secretary Doug Collins, Trump asked: “How are you doing with the suicide rates?”

Collins only spoke for thirty seconds, but managed a mention of psychedelics. “I worked with Secretary Kennedy and others on the idea of opening up the possibility of psychedelic treatment and others that give us an opportunity”, he said, adding: “We gotta research it, make sure it’s good, but it’s opening up that possibility.”

That was the second time this week that the VA head mentioned the class of substances. On Monday, No Fallen Heroes Chairman and psychedelics advocate Matthew Buckley replied to one of the Secretary’s tweets, complaining that he had not shown leadership on psychedelic-assisted therapy.

Collins responded, telling Buckley: “As I’ve said before, we are looking at psychedelic treatments as well as other alternative treatments such as hyperbaric oxygen chambers, and virtual reality therapy.” “We are also working with Congress to approve more treatments”, he added.

Prior to that, Collins discussed psychedelics at length on The Shawn Ryan Show, as we covered in detail in Bulletin 193.

It remains unclear, for now, precisely what this ‘work’ entails or is intended to produce…

Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…